Lawrence Chun

发表

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.

Stacie L. Bulfer, O. Rosen, M. Heinrich, 2019, Cancer cell.

The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors

J. Condeelis, Xiaoming Chen, Joan G. Jones, 2017, Molecular Cancer Therapeutics.

The Selective Tie 2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie 2 Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors

J. Condeelis, Xiaoming Chen, Joan G. Jones, 2017 .

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.

Xiwen Ma, Shih-Hsun Chen, G. Plowman, 2015, Cancer cell.

Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.

L. Stewart, R. V. van Etten, T. Haack, 2011, Cancer cell.

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

L. Stewart, Michael D. Kaufman, D. Flynn, 2015, Molecular Cancer Therapeutics.

Novel human D-amino acid oxidase inhibitors stabilize an active-site lid-open conformation

Scott P. Brown, L. Hardy, L. Pollegioni, 2014, Bioscience reports.

Mechanism of inhibition for N6022, a first-in-class drug targeting S-nitrosoglutathione reductase.

G. Rosenthal, L. Green, J. P. Richards, 2012, Biochemistry.

Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.

P. Hipskind, D. Clawson, D. Manglicmot, 2015, Journal of medicinal chemistry.

Inhibition of RAF Isoforms and Active Dimers by LY 3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers Graphical

Xiwen Ma, Shih-Hsun Chen, G. Plowman, 2015 .

Structure-activity relationships of pyrrole based S-nitrosoglutathione reductase inhibitors: pyrrole regioisomers and propionic acid replacement.

S. Mutka, D. Colagiovanni, G. Rosenthal, 2011, Bioorganic & medicinal chemistry letters.

Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.

S. Mutka, D. Colagiovanni, G. Rosenthal, 2011, ACS medicinal chemistry letters.